DDInter1174 DDInter1658
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Methotrexate {u} (Compound) resembles {v} (Compound) Raltitrexed
Methotrexate {u} (Compound) resembles {v} (Compound) Tetrahydrofolic acid
Methotrexate {u} (Compound) treats {v} (Disease) stomach cancer
Methotrexate {u} (Compound) binds {v} (Gene) SLC16A1
Methotrexate {u} (Compound) upregulates {v} (Gene) PDLIM1
Methotrexate {u} (Compound) is included by {v} (Pharmacologic Class) Folic Acid Metabolism Inhibitors
Methotrexate {u} (Compound) downregulates {v} (Gene) TMEM50A
Methotrexate {u} (Compound) causes {v} (Side Effect) Ecchymosis
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Haloperidol
Methotrexate (Compound) resembles Raltitrexed (Compound)
Methotrexate (Compound) resembles Tetrahydrofolic acid (Compound)
Methotrexate (Compound) treats stomach cancer (Disease)
Methotrexate (Compound) binds SLC16A1 (Gene)
Methotrexate (Compound) upregulates PDLIM1 (Gene)
Methotrexate (Compound) is included by Folic Acid Metabolism Inhibitors (Pharmacologic Class)
Methotrexate (Compound) downregulates TMEM50A (Gene)
Methotrexate (Compound) causes Ecchymosis (Side Effect)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Haloperidol